Novo Nordisk Pharmatech ranked among the top one percent most sustainable companies

Koege, Denmark: – Leading insulin and quaternary ammonium compounds (Quats) specialist Novo Nordisk Pharmatech A/S has been ranked among the top 1% of companies assessed for the EcoVadis Sustainability Assessment Report, gaining a Platinum Medal.

This is the first time that Novo Nordisk Pharmatech is part of the EcoVadis report, which over the past 15 years has become the world´s most trusted business sustainability rating, now covering more than 100.000 companies from over 200 industries in some 175+ countries.

Stakeholder performance

As companies worldwide focus more and more on sustainability, for audit and investor assessments, it was important for Novo Nordisk Pharmatech to become part of the EcoVadis network, providing a recognised way to share performance metrics with relevant stakeholders within areas such as Environment, Labour & Human Rights, Ethics, and Sustainable Procurement.

“We continuously strive to drive our business sustainably. All employees at Novo Nordisk Pharmatech can be proud of this result, as it can only be done because sustainability is integrated into everything we do,” commented Novo Nordisk Pharmatech CEO Ulla Grove Krogsgaard Thomsen.

“The choice of EcoVadis as a partner was easy. Their expert panel is impartial, and EcoVadis is a serious and universally recognized platform. The platform also allows benchmarking against other companies within the same industry,” noted Ms. Thomsen.

Triple Bottom Line ambition

Measuring and reporting on environmental, financial, and social performance – called “The Triple Bottom Line” – by considering the use of resources, CO2 emission, and waste to be the most material impacts on the environment across the value chain has formed the basis of Novo Nordisk Pharmatech´s ambition for several years.

Despite the positive findings from the survey, especially within Environment and Labour & Human rights, Novo Nordisk Pharmatech still sees room for improvement, for example on its Measurement and Reporting performance. The company’s goal is to update the EcoVadis survey once a year based on the organization’s suggestions for improvement.

About Novo Nordisk Pharmatech A/S

Novo Nordisk Pharmatech A/S is a global and leading manufacturer of pharmaceutical aids for the pharmaceutical and biopharmaceutical industries. The company specializes in producing quaternary ammonium compounds (Quats) used as active pharmaceutical ingredients (APIs) and excipients as well as delivering Recombinant Insulin for use in cell culture media to enhance cell growth and viability, and productivity.

Novo Nordisk Pharmatech A/S helps the world´s largest pharmaceutical and biopharmaceutical industries reduce their risk for raw materials by using pharma-grade products with a high level of consistency, purity, quality, and reliability.

Novo Nordisk Pharmatech A/S was established in 1949 as Ferrosan Fine Chemicals and acquired by Novo Nordisk in 1986. The company is operating as a division of Novo Nordisk A/S from Køge, south of Copenhagen.

You can learn more about Novo Nordisk Pharmatech at novonordiskpharmatech.com.

Resources

Click on Contact Novo Nordisk Pharmatech to access the full EcoVadis 2022 Sustainability report.